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Abstract 
Background: Methadone Maintenance Treatment is a useful method for opioid dependents, which 
results in harm reduction and increased quality of life in opioid dependents. The prevalence of 
psychiatric disorders in addicts is higher than in the general population which can interfere with the 
course and treatment of substance dependents and decrease the efficacy of treatment. 
Methods: This descriptive, cross-sectional study was aimed to determine the correlation between 
psychiatric disorders and methadone dosage. It was performed on 154 patients of Kerman Shahid 
Beheshti Hospital’s Methadone Clinic during a six month period from Dec 2010 to Jul 2011. The study 
population was chosen by convenience sampling. The searching tools were Socio-Demographic 
Questionnaire, psychiatric structured interview based on DSM-IV-TR, Beck Depression Inventory, 
Young Mania Rating Scales, and Anxiety and Depression Rating Scales. 
Findings: Significant correlations were observed between increased methadone dosage and antisocial 
personality disorder. In addition, significant positive correlations were observed between increased 
methadone dosage and Hamilton anxiety scores, Hamilton depression scores and Young Mania scores. 
Conclusion: High methadone dosage may be a marker of coexisting psychiatric disorders in patients on 
methadone maintenance treatment which indicates the necessity of devoting further attention to this 
group. Psychiatric services should be open and accessible to the patients, especially those who seek 
treatment voluntarily. Early diagnosis and treatment of patients with coexisting psychiatric disorders 
may increase the efficacy of methadone maintenance treatment. 
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Introduction  
Dependence on opoid is a chronic and mainly 
recurring disorder which causes many medical 
difficulties including AIDS and hepatitis as well 
as social problems. Due to its chronic feature, 
long-term and even sometimes permanent 
treatment is necessary through replacing 
opoids with substitutes such as methadone for 
alleviating physical and psychosocial 
hardships.1-3 
Methadone is a synthetic narcotic eaten 
orally that can substitute heroin. Methadone is 
given to the addicted patients instead of their 
administered drug and causes placation of 
withdrawal symptoms. Methadone 
maintenance is prescribed as far as it is possible 
to make the patient quit this drug, which is 
itself addictive, at later times. Metahdone 
maintenance reduces death risk up to 70%, 
leads to a decrease in consumption of illegal 
narcotics and prevents from other drug abuse 
items, decreases crime rate, and finally lowers 
the risk of suffering from a variety of infectious 
diseases, most imprtantly AIDS and hepatitis B 
and C.  It also causes 80% reduction in family 
fights and quarrels. The only demerit is that the 
patinet might remain dependent on another 
narcotic drug.4,5 
People who abuse and suffer from 
dependence on narcotic drugs will also incur 
other disorders.4 Simultaneous reliance on 
several substances, depression and anxiety, and 
personality disarrangement are among the 
disorders associated with addiction.6 Mood 
disorders are the most prevailing kind of 
psychological suffering in heroin addicts and 
12-24% of heroin-addicted people are 
simultaneously depressed.7 Overall, it can be 
stated that psychiatric disorders are more 
prevalent among addicted individuals than the 
public population.8 Diagnosis of these disorders 
plays a decisive role in medication and 
prognosis.9 
Medication of drug abuse is less effective in 
the presence of psychiatric diseases and 
treatment becomes less efficient as the mental 
symptoms grow.10 Compared to the group of 
people who merely have addiction diagnosis, 
the addicted people simultaneously suffering 
from mental disorders require higher dosages 
of methadone and longer time of 
administration to reach a stable state. They 
proceed less successfully in the methadone 
maintenance treatment and risk of withdrawal 
medication is high for them.11 In the cases 
where the addicted patient does not accept to 
withdraw, measures must be taken so that the 
grounds are provided for lowering dangers 
caused by drug abuse.12 In Iran, damage 
alleviation programs have been ratified and 
executed since 2001 in national and provincial 
scales; methadone maintenance treatment is 
one of the major services provided in such 
programs.13 
Taking into account high costs of methadone 
maintenance programs, the chance of realizing 
objectives and interests of this plan would fail 
in the event of inconsistency of patients to 
follow the medication procedures. This study 
was conducted with the intent of determining 
the relationship between administered dosages 
of methadone and comorbid psychiatric 
disorders in volunteer patients admitted to the 
outpatient methadone clinic of Shahid Beheshti 
Psychiatric Hospital, Kerman, Iran. Having 
studied this relationship, the necessity for 
paying attention to psychiatric interventions in 
methadone-treated patients is further 
accentuated because by medicating the 
simultaneous psychiatric disorders, besides 
lowering the administered dosage of 
methadone which in turn reduces medication 
expenses, the methadone-induced 
complications will decrease and also the 
patients will become more consistent in the 
methadone maintenance treatment. 
Accordingly, objectives of the program are 
further realized bringing benefits to both the 
individual and the society. 
 
Methods 
The current study is a cross-sectional 
descriptive survey. The studied population 
comprised of 154 individuals selected through 
simple sampling method from all patients 
admitted to the methadone clinic of Shahid 
Beheshti Hospital, Kerman, within a 6-month 
period (February 2011-August 2011).  
First the participation in the research was 
explained by clinic nurses to the people treated 
with methadone who refer to the clinic every day 
to receive methadone. Demographic details and 
administered methadone data forms were then 
recorded by the nurses based on patient files. 
Subsequently, a psychiatrist aide held clinical 
psychiatric interviews with all participants; the 
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interview was arranged in accordance with DSM-
IV–TR standard. Finally, Back’s depression 
questionnaire was completed by the patients 
themselves (self-report) and Hamilton’s 
depression and anxiety scales and Young Mania 
Rating Scale were completed by the aide. 
The patients’ methadone dosage had been 
adjusted prior to entry into the program 
according to the methadone maintenance 
protocol of the Ministry of Health and Medical 
Education. Those patients who participated in 
the program had received a fixed dosage of 
methadone for at least two weeks. The 
interviewer had no knowledge of the 
administered dosage of methadone while doing 
the interview or completing the questionnaires. 
The data were statistically analyzed using SPSS 
software 17 and ANOVA and Spearman tests. 
 
Results 
Out of the 154 studied patients, 147 people 
were male (95.5%) and 7 were female (4.5%). 
Minimum and maximum methadone dosages 
in the studied individuals were 10 mg and 220 
mg, respectively; average methadone dosage 
was 86.16 mg. 
According to the clinical psychiatric 
interview structured based on DSM-IV-TR, 38 
people (24.7%) had major depressive disorder 
(MDD), 7 (4.5%) suffered from bipolar mood 
disorder (BMD), 13 had anxiety disorders 
(including OCD, PANIC, PTSD), 9 people had 
record of ADHD in childhood (based on 
description of childhood times), 4 people 
suffered from adult ADHD, and 17participants 
(11%) suffered from major depressive disorder 
and anxiety disorders simultaneously. 
Moreover, 22 individuals (14.3%) had anti-social 
personality disorder, 24 (15.6%) had borderline 
personality disorder and 7 people (4.5%) 
suffered from paranoid personality disorder. 
As shown in table 1, the average 
administered dosage of methadone was 86.42 
mg for those who had no disorder of “I” axis. 
This figure was 103.42, 75.71, 93.46, 71.76, and 
82.35 (mg) respectively for the persons with 
MDD, BMD, anxiety disorders (including OCD, 
PANIC, and PTSD), childhood ADHD, adult 
ADHD, and finally, those simultaneously 
having major depressive disorder and anxiety 
disorders.  
According to the statistical survey 
conducted by using analysis of variance and 
observing the required preconditions, there is 
no significant statistical correlation between 
levels of suffering from psychiatric disorders of 
“I” axis and methadone dosage. 
According to table 2, the average 
administered dosage of methadone was 81.73 
mg in people who did not have personality 
disorder of “II” axis; this figure is respectively 
110.68, 96.46, and 103.57 for those suffering 
from anti-social personality disorder, 
borderline personality disorder, and paranoid 
personality disorder.  
Based on the statistical analysis, there is a 
statistically significant correlation between 
psychiatric disorders of “II” axis and 
administered dosage of methadone (P = 0.005). 
Results of post-hoc tests (TUKEY test) proved that 
the participants suffering from anti-social 
personality disorder require a significantly higher 
dosage of methadone compared to those who 
have no personality disorder; but such an impact 
was not observed in other personality disorders. 
For the studied patients, maximum and 
minimum scores were 1 and 61 in Back’s 
depression questionnaire and average score was 
20.55. Minimum, maximum, and mean scores 
were respectively 0, 25 and 8.12 for Hamilton’s 
depression scale. The same scores were 0, 21, 
and 5.6 for Hamilton’s anxiety scale, 
respectively. In Young Mania Rating Scale, these 
figures were 0, 7, and 0.39 in the same order. 
According to table 3: 
There is no significant statistical correlation 
between Back’s depression test scores in the 
studied individuals and methadone dosage  
(P = 0.140), and the relationship of two 
variables is not extendable.  
There is a significant statistical relationship 
between Hamilton’s depression test scores in 
the studied individuals and methadone dosage 
(P = 0.010), and scores of Hamilton’s depression 
test and administered methadone dosage are 
positively correlated; i.e. administered dosage 
of methadone increases with higher scores of 
Hamilton’s depression test scores.  
There is a significant statistical relationship 
between Young Mania Rating Scale scores in 
the studied individuals and methadone dosage 
(P = 0.010), and scores of Young Mania Rating 
Scale and administered methadone dosage are 
positively correlated; i.e. administered dosage 
of methadone increases with higher scores of 
Young Mania Rating Scale scores. 
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Discussion 
Based on the clinical interview in accordance 
with DSM-IV-TR in the current study, the most 
prevalent psychiatric disorders in the 
methadone-treated patients were major 
depressive disorder (24.7%), borderline 
personality disorder (15.6%), anti-social 
personality disorder (14.3%), and simultaneous 
anxiety disorders and major depressive 
disorder (11%). 
Totally, 51.2% of methadone-treated patients 
suffered from psychiatric disorders of “I” axis 
and 34.4% of them had some sort of personality 
disorder with borderline personality disorder 
as the most prevailing item (15.6%). the latter 
result is not in agreement with Brooner et al.’s 
study,  in which anti-social personality disorder 
is the most frequent case (33.9%).14 One of the 
reasons for different results of the present study 
might be due to the fact that the studied 
individuals have been selected from volunteers 
admitted to an academic psychiatric center for 
methadone maintenance, and hence 
considering the higher probability of 
attendance of people with anti-social 
personality disorder in other places such as 
prisons, and the likelihood of their avoidance 
from being admitted to psychiatric centers, the 
aforementioned disorder in our statistical 
population is observed less frequently than the 
actual level. Moreover, people with borderline 
personality disorder are more in need of 
psychiatric medication due to lack of 
sensational and behavioral stability and are 
likely to refer more frequently to academic 
hospitals because of their acquaintance with 
such medical centers. Furthermore, this 
difference might result from exceeded 
abundance of borderline personality disorder 
compared to the past, which must be 
investigated in the society.  
On the other hand, 34.4% of methadone- 
 
Table 1. Correlation of methadone dosage and psychiatric disorders of “I” axis according to DSM-IV-TR (Diagnostic 
and statistical manual of mental disorders, 4th Edition, Text revision) in research samples 
 Quantity Average methadone dosage Standard deviation P-value 
MDD 38 103.42 44.6  
 
 
0.130 
Anxiety Disorders 13 93.46 30.0 
BMD 7 75.71 42.6 
Childhood ADHD record 9 71.67 23.1 
Adult ADHD 4 70.00 43.0 
MDD + Anxiety D. 17 82.35 29.7 
Total studied patients 154 89.16 38.5 
MDD: Major depressive disorder; BMD: Bipolar mood disorder; ADHD: Attention deficit hyperactivity disorder 
 
Table 2. Correlation of methadone dosage and psychiatric disorders of “II” axis according to DSM-IV-TR (Diagnostic 
and statistical manual of mental disorders, 4th Edition, Text revision) in research samples 
 Quantity Average methadone dosage Standard deviation P-value
Without certain diagnostic disorder 101 81.73 34.8  
 
0.005 
Anti-social personality disorder 22 110.68 43.3 
Borderline personality disorder 24 96.46 39.2 
Paranoid personality disorder 7 103.57 45.1 
Total studied patients 154 89.16 38.5 
 
Table 3. Correlation of methadone dosage and scores of Back, Hamilton’s Depression, Hamilton’s Anxiety, and Young 
Mania Rating Scales disorder tests  
Methadone Dosage  
 Rho (Spearman) P-value 
Beck’s depression test 0.119 0.140 
Hamilton’s depression test 0.207 0.010 
Hamilton’s Anxiety Scale 0.182 0.024 
Young Mania Rating Scale 0.172 0.034 
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treated individuals suffered from one 
personality disorder, which is relatively in 
alignment with the findings of the research by 
Brooner et al. where 40.5% of addicts had 
personality disorders.14  
According to results of the current study, 
suffering from a psychiatric disorder of “I” axis 
did not have a significant impact on the 
administered dosage of medicine for 
methadone-treated patients. In Maremmani et 
al.’s studies, however, people showing 
symptoms of somatization, depression and 
anxiety and also bipolar disorder required 
higher dosages of methadone.15 Moreover, in a 
study by Eslami et al. conducted similar to the 
current research based on psychiatric disorder 
diagnosis of “I” and “II” axes through 
DSM-IV-TR interview, depression, anxiety and 
bipolar disorders were accompanied with an 
increase in initial methadone dosage.16  
There was a statistically significant 
correlation between psychiatric disorders of 
“II” axis and administered dosage of medicine 
in methadone-treated patients. Results of post-
hoc tests (TUKEY test) proved that the people 
suffering from anti-social personality disorder 
significantly need higher dosage of methadone 
compared to those who have no personality 
disorders; but such an impact was not observed 
in other personality disorders. This result is not 
in agreement with the findings of studies by 
Murray et al., Treece and Nicholson, 
Maremmani et al., and Eslami et al. who 
inferred that the patients suffering from 
schizoid and paranoid personality disorders 
and anti-social and borderline disorders need 
higher methadone dosages.15-19 
There was no statistically significant 
correlation between scores of Back’s depression 
test and administered dosage of medicine in 
methadone-treated individuals. This lack of 
correlation seems to result from the improper 
collaboration of some patients in completing 
Back depression questionnaire in self-report 
form, and in some cases this drawback is 
caused by careless and completion without 
reading of questionnaires. In addition, the bias 
observed in the results might be related to 
excessive depiction of symptoms in the Back’s 
questionnaire by some patients; this could 
originate from drug abuse and/or receiving 
methadone overdose.  
There was a significant statistical correlation 
between administered methadone dosage and 
scores of Hamilton’s depression test, where 
methadone dosage increased with a higher 
score of Hamilton’s depression test. This result 
is in accordance with findings of the study by 
Peles et al. in which score of Hamilton’s 
depression test is positively correlated to 
methadone dosage.20  
Furthermore, a significant statistical 
corre-lation was also observed between 
administered methadone dosage and scores of 
Hamilton’s anxiety test, where methadone 
dosage increased with a high score of 
Hamilton’s anxiety test. 
There also exists a significant statistical 
correlation between administered methadone 
dosage and scores of Young Mania Rating 
Scale, and methadone dosage increases with the 
ascending score of Young Mania Rating Scale.  
Results of the current research and other 
studies are indicative of psychiatric disorders of 
“I” and “II” axes in methadone-treated patients. 
The evidence suggest that although 
simultaneous presence of “I” axis psychiatric 
disorders had no correlation with the increase 
in administered methadone dosage; there was a 
positive correlation between medicine dosage 
and intensity of anxiety, depression, and mania 
symptoms. Exceeded intensity of symptoms led 
to an increment in methadone dosage. Besides, 
the addicted patients with simultaneous 
psychiatric disorders are less consistent in 
following the treatment procedures. They are 
highly prone to quitting the treatment and need 
higher dosages and a longer time for 
stabilization.21  
Therefore, high methadone dosage might 
serve as a marker for the simultaneous presence 
of other psychiatric disorders in methadone-
treated patients. This implies the necessity for 
further investigation of patients who need 
higher dosages of methadone for comorbidity 
because diagnosis and medication of 
simultaneous disorders in such patients would 
result in the reduction of administered 
methadone dosage, alleviation of methadone 
complications (adverse side effects), and 
ultimately, decrease in financial costs. More 
importantly, these benefits will improve the 
consistency of patients in methadone treatment 
leading to the further realization of the 
objectives of the current research. 
 
Recommendations  
Taking into account the above discussions,  
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availability of psychiatric services for patients, 
especially for those voluntarily seeking help 
and medication, coupled with timely diagnosis 
and treatment of individuals suffering from 
simultaneous psychiatric disorders will 
apparently contribute to the improvement of 
benefits of methadone maintenance treatment 
and further realization of the current research 
objectives. 
Future studies are recommended to 
investigate the medical interventions and also 
to evaluate the variations in administered 
methadone dosage following the treatment.  
 
Limitations 
Abuse of drugs by patients and withdrawal  
symptoms could cause bias in the clinical 
assessment and also findings of the questionnaire 
and might lead to mistaken diagnosis of anxiety 
and depression disorders. It is recommended that 
patients be analyzed in terms of abuse of drug 
and narcotic in the future studies.  
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 ﺑﻴﻤﺎران ﺗﺤﺖ ﭘﺰﺷﻜﻲ ﻫﻤﺮاه در ارﺗﺒﺎط ﺑﻴﻦ دوز ﻣﺼﺮﻓﻲ ﻣﺘﺎدون ﺑﺎ اﺧﺘﻼﻻت روان ﺑﺮرﺳﻲ
  درﻣﺎن ﻧﮕﻬﺪارﻧﺪه ﺑﺎ ﻣﺘﺎدون
  
  4ﺷﻬﺮزاد ﻣﻈﻬﺮي دﻛﺘﺮ، 3ﺗﺒﺮﻳﺰي ﺷﻴﻮا ﻣﺠﻴﺪي، 2دﻛﺘﺮ آرﻣﺎن ﻣﺴﻌﻮدي ،1دﻛﺘﺮ ﻧﻮﺷﻴﻦ ﭘﺮورش
  
  
  ﭼﻜﻴﺪه
ﻛﻪ ﺳﺒﺐ ﻛﺎﻫﺶ  اﺳﺖاﻓﺮاد واﺑﺴﺘﻪ ﺑﻪ ﻣﻮاد اﻓﻴﻮﻧﻲ ﻫﺎي درﻣﺎﻧﻲ ﻣﻔﻴﺪ در  درﻣﺎن ﻧﮕﻬﺪارﻧﺪه ﺑﺎ ﻣﺘﺎدون از ﺟﻤﻠﻪ روش :ﻣﻘﺪﻣﻪ
ﺗﺮ از ﺟﻤﻌﻴﺖ  ﭘﺰﺷﻜﻲ در ﻣﻌﺘﺎدان ﺑﺴﻴﺎر ﺑﻴﺶ ﺷﻴﻮع اﺧﺘﻼﻻت روان. ﺷﻮد اﻓﺮاد ﻣﻲ اﻳﻦ آﺳﻴﺐ و اﻓﺰاﻳﺶ ﻛﻴﻔﻴﺖ زﻧﺪﮔﻲ
  .و ﺳﺒﺐ ﻛﺎﻫﺶ ﻛﺎراﻳﻲ درﻣﺎن ﺷﻮد ﺮدهﻛ اﻳﺠﺎد ﺗﻮاﻧﺪ در ﺳﻴﺮ درﻣﺎن اﻓﺮاد واﺑﺴﺘﻪ ﺑﻪ ﻣﻮاد ﺗﺪاﺧﻞ ﺑﺎﺷﺪ ﻛﻪ ﻣﻲ ﻋﻤﻮﻣﻲ ﻣﻲ
ﭘﺰﺷﻜﻲ ﻫﻤﺮاه  ﺗﻌﻴﻴﻦ ارﺗﺒﺎط ﺑﻴﻦ دوز ﻣﺼﺮﻓﻲ ﻣﺘﺎدون ﺑﺎ اﺧﺘﻼﻻت روان ،ﺑﺎ ﻫﺪف ﺣﺎﺿﺮ ﺗﻮﺻﻴﻔﻲ - ﻣﻘﻄﻌﻲ ﻣﻄﺎﻟﻌﻪ :ﻫﺎ روش
 6ﻳﻚ دوره و در  9831 - 09ﺳﺎل ﻛﻨﻨﺪه ﺑﻪ ﻛﻠﻴﻨﻴﻚ ﻣﺘﺎدون ﺑﻴﻤﺎرﺳﺘﺎن ﺷﻬﻴﺪ ﺑﻬﺸﺘﻲ ﻛﺮﻣﺎن در  ﻣﺮاﺟﻌﻪ 451ﺑﺮ روي 
ﻧﺎﻣﻪ  ﭘﺮﺳﺶ ،RT- VI MSD ﭘﺰﺷﻜﻲ ﺑﺮ اﺳﺎس وانﻳﺎﻓﺘﻪ ر ﻣﺼﺎﺣﺒﻪ ﺳﺎﺧﺘﺎر ﺷﺎﻣﻞ ﭘﮋوﻫﺶ ﻫﺎياﺑﺰار. اﻧﺠﺎم ﺷﺪ ﻣﺎﻫﻪ
اﺿﻄﺮاب و اﻓﺴﺮدﮔﻲ  ﻧﺎﻣﻪ ﭘﺮﺳﺶ و ainaM gnuoYﻫﺎي  ﻣﻘﻴﺎس ،kceBﻧﺎﻣﻪ اﻓﺴﺮدﮔﻲ  ﭘﺮﺳﺶ ﺷﻨﺎﺧﺘﻲ، ﺟﻤﻌﻴﺖ
  .ﺑﻮد notlimaH
ﻫﻤﭽﻨﻴﻦ (. P < 0/10)داري داﺷﺖ  اﺧﺘﻼل ﺷﺨﺼﻴﺖ ﺿﺪ اﺟﺘﻤﺎﻋﻲ ﺑﺎ اﻓﺰاﻳﺶ دوز ﻣﺘﺎدون ﻣﺼﺮﻓﻲ ارﺗﺒﺎط ﻣﻌﻨﻲ :ﻫﺎ ﻳﺎﻓﺘﻪ
و اﻓﺰاﻳﺶ دوز ﻣﺘﺎدون ﻣﺼﺮﻓﻲ ارﺗﺒﺎط  ainaM gnuoYﻣﻘﻴﺎس  ،notlimaHﻫﺎي اﻓﺴﺮدﮔﻲ و اﺿﻄﺮاب  ﻘﻴﺎسﺑﻴﻦ ﻧﻤﺮات ﻣ
  .(P < 0/050) ﻣﺸﺎﻫﺪه ﺷﺪداري  ﻣﻌﻨﻲ
اﺧﺘﻼﻻت ﻧﺸﺎﻧﻪ وﺟﻮد  ﻣﺘﺎدونﺑﺎﻻي  دوز، ﻣﻤﻜﻦ اﺳﺖ ﻧﮕﻬﺪارﻧﺪه ﺑﺎ ﻣﺘﺎدون ﺗﺤﺖ درﻣﺎن در ﺑﻴﻤﺎران :ﮔﻴﺮي ﻧﺘﻴﺠﻪ
در دﺳﺘﺮس ﺑﻮدن ﺧﺪﻣﺎت  ﺑﻨﺎﺑﺮاﻳﻦ،. ﺑﺎﺷﺪ ﺗﺮ ﺑﻪ اﻳﻦ ﮔﺮوه ﻣﻲ ﺗﻮﺟﻪ ﺑﻴﺶ ﻫﻤﺰﻣﺎن ﺑﻮده و ﺑﻴﺎﻧﮕﺮ ﻟﺰومﭘﺰﺷﻜﻲ  روان
ﺗﺸﺨﻴﺺ و درﻣﺎن ﺑﻪ ﻣﻮﻗﻊ  و ﻫﻤﭽﻨﻴﻦ ﻫﺎﻳﻲ ﻛﻪ داوﻃﻠﺒﺎﻧﻪ ﺑﻪ دﻧﺒﺎل درﻣﺎن ﻫﺴﺘﻨﺪ ﭘﺰﺷﻜﻲ ﺑﺮاي ﺑﻴﻤﺎران، ﺑﻪ وﻳﮋه آن روان
  .ﺷﻮد ن ﻣﻲﻫﻤﺰﻣﺎن ﻣﻮﺟﺐ اﻓﺰاﻳﺶ ﻛﺎراﻳﻲ درﻣﺎن ﻧﮕﻬﺪارﻧﺪه ﺑﺎ ﻣﺘﺎدو ،ﭘﺰﺷﻜﻲ اﻓﺮاد ﻣﺒﺘﻼ ﺑﻪ اﺧﺘﻼﻻت روان
  .ﭘﺰﺷﻜﻲ، واﺑﺴﺘﮕﻲ ﺑﻪ ﻣﻮاد درﻣﺎن ﻧﮕﻬﺪارﻧﺪه ﺑﺎ ﻣﺘﺎدون، اﺧﺘﻼﻻت روان :واژﮔﺎن ﻛﻠﻴﺪي
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